Aastrom Biosciences Inc (NASDAQ:ASTM) posted its quarterly earnings results on Thursday. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.34, AnalystRatings.NET reports. On a related note, analysts at Zacks reiterated a “neutral” rating on shares of the company in a research note on Friday, March 14th. They now have a $5.00 price target on the stock. Aastrom Biosciences Inc (NASDAQ:ASTM) stock performance was -4.16% in last session and finished the day at $4.15. Traded volume was 343,290.00million shares in the last session and the average volume of the stock remained 451.86K shares. The beta of the stock remained 0.85. Aastrom Biosciences Inc (NASDAQ:ASTM) insider ownership is 3.27%.

Levi & Korsinsky, LLP is investigating Puma Biotechnology, Inc. (NYSE:PBYI) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company. Puma Biotechnology Inc (NYSE:PBYI) dropped -7.16 percent to $61.85 Tuesday on volume of 371,356.00million shares. The intra-day range of the stock was $61.16 to $66.38. Puma Biotechnology Inc (NYSE:PBYI) has a market capitalization of $1.86billion.

Oncolytics Biotech Inc. (NASDAQ:ONCY) on 20 May 2014 announced that an abstract detailing early results from translational study looking at the intravenous administration of REOLYSIN to patients with primary or metastatic brain tumors is now available on the ASCO Annual Meeting abstract website athttp://abstracts.asco.org. The conference is being held from May 30th to June 3rd, 2014 in Chicago, Illinois. Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)’s stock on May 20, 2014 reported a decrease of -2.22% to the closing price of $1.32. Its fifty two weeks range is $1.20 -$3.50. The total market capitalization recorded $114.08million. The overall volume in the last trading session was 699,702.00million shares. In its share capital, ONCY has 85.81million outstanding shares.

Clovis Oncology Inc. (NASDAQ:CLVS) declared after the finishing bell on Monday that the FDA has agreed on the Breakthrough Therapy Designation for its inquiries agent CO-1686 as monotherapy for the action of second-line EGFR mutant NSCLC in enduring with the T790M change. Shares were moving up 4% during the Tuesday session. On Tuesday, shares of Clovis Oncology Inc (NASDAQ:CLVS) advanced 0.19% to close the day at $56.88. Company monthly performance is recorded as 4.29%. Clovis Oncology Inc (NASDAQ:CLVS) quarterly revenue growth is -21.45%.

Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares declined 4.9% on 05 May 2014 after the company reported a wider-than-expected loss for the first quarter of 2014. The company posted a loss of 24 cents per share in the first quarter of 2014, wider than the year-ago quarter loss of 23 cents and the Zacks Consensus Estimate of a loss of 20 cents per share. In the first quarter, Idenix Pharmaceuticals Inc (NASDAQ:IDIX)’s revenues were ($3) million, down from $0.9 million in the year-ago quarter. The $3.9 million decline reflected charges against revenues due to the impact of Novartis ‘ ( NVS ) stock subscription rights. Research and development expenses decreased 12.2% from the first quarter of 2013 to $21.1 million. This decrease was mainly due to the discontinuation of development of IDX184 and IDX19368 in early 2013 and IDX20963 in 2014, partially offset by increased expenses due to the development of IDX21437. General and administrative expense surged 36.7% year over year to $10.3 million. This increase was driven by patent litigation and other costs. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock performance was 3.56% in last session and finished the day at $6.25. Traded volume was 1.87.00million shares in the last session and the average volume of the stock remained 1.29M shares. The beta of the stock remained -0.04. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) insider ownership is 25.11%.